General Biotechnology

Most companies treat out-licensing like a last-minute scramble.
They wait until a patent is already wobbling—then scramble to “find partners,” negotiate terms, and hope the market is still interested. By then, the value has already leaked out: competit…

Pharma doesn’t just “win” patents—it engineers time.
In a world where blockbuster drugs face relentless pressure from generics and biosimilars, the real competitive advantage often isn’t the original patent grant. It’s what comes after: the ability to …

Big Pharma doesn’t just “run out” of patents. It chooses what to abandon—and what to double down on.
That’s the uncomfortable takeaway from the latest analysis at DrugPatentWatch on abandoned patents and what they reveal about pipeline priorities. When…

AI is supposed to make teams faster. But in pharma, speed without precision can quietly destroy brand value.
Here’s the uncomfortable truth: hallucinations—confident, incorrect outputs—don’t just create “bad information.” They can trigger regulatory ri…

The cliff is coming. The question is whether you can see it.
In pharma, “the cliff” isn’t a metaphor—it’s a calendar. It’s the moment exclusivity ends, the moment generic competition becomes legally possible, and the moment pricing power can evaporate …

Generic drugs are supposed to be boring. But the path to generic profits is anything but. A new analysis from DrugPatentWatch lays out a stark contrast between two playbooks: the U.S. “niche strategy” and India’s “mass market model.” Both can print mon…

Evergreen patents aren’t “new” inventions—they’re often new paperwork.
That’s the core warning in a recent DrugPatentWatch post on how companies can extend exclusivity by exploiting the FDA’s Orange Book mechanics—specifically through sequential listin…

Most drug companies still treat the 505(b)(2) and 505(b)(1) pathways like interchangeable “regulatory routes.” They aren’t.
And that misunderstanding is expensive—measured in months, dollars, and, ultimately, the credibility of your development plan wi…

Patent gaps aren’t “accidents.” They’re design features—often hiding in plain sight.
For years, the industry has talked about patent cliffs like they’re weather: unpredictable, unavoidable, and mostly outside anyone’s control. But the real story is m…

The 20-year patent is supposed to be a finish line. In pharma, it’s often just the starting gun.
For years, the public narrative has been simple: drug patents last 20 years, and once they expire, competition arrives. But the reality—especially in the U…